Report of Foreign Issuer (6-k)
October 16 2017 - 7:59AM
Edgar (US Regulatory)
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending
16 October
2017
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
GlaxoSmithKline plc (the
'
Company
')
Transaction notification
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Ms E Walmsley
|
b)
|
Position
/ status
|
Chief
Executive Officer
|
c)
|
Initial
notification /
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of
the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature of
the
transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 12 October 2017
on Ordinary Shares held in the Company's Deferred Investment Award
Programme.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.2425
|
262.743
|
d)
|
Aggregated
information
Aggregated
volume
Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2017-10-12
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr R G Connor
|
b)
|
Position
/ status
|
President, Global Manufacturing & Supply
|
c)
|
Initial
notification /
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of
the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature of
the
transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 October 2017, on Ordinary
Shares held in the Company's Deferred Investment Award
Programme.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.2425
|
105.097
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2017-10-12
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr
B McNamara
|
b)
|
Position
/ status
|
CEO,
GSK Consumer Healthcare
|
c)
|
Initial
notification /
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of
the financial
instrument
|
GlaxoSmithKline
plc American Depositary Shares ('ADSs')
ISIN:
US37733W1053
|
b)
|
Nature of
the
transaction
|
Increase
in notional interest in ADSs following the re-investment of
dividends paid to shareholders on 12 October 2017 on ADSs held in
the Company's Deferred Investment Award Programme.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
$40.9497
|
330.748
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2017-10-12
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr
D S Redfern
|
b)
|
Position
/ status
|
Chief
Strategy
Officer
|
c)
|
Initial
notification /
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of
the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature of
the
transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 October 2017 on Ordinary
Shares held in the Company's Deferred Investment Award
Programme.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.2425
|
105.097
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2017-10-12
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Ms C
Thomas
|
b)
|
Position
/ status
|
Senior
Vice President, HR
|
c)
|
Initial
notification /
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of
the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature of
the
transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 October 2017 on Ordinary
Shares held in the Company's Deferred Investment Award
Programme.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.2425
|
105.097
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2017-10-12
|
f)
|
Place
of the transaction
|
n/a
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Dr P J
T Vallance
|
b)
|
Position
/ status
|
President,
R&D
|
c)
|
Initial
notification /
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of
the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature of
the
transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 12 October 2017 on Ordinary
Shares held in the Company's Deferred Investment Award
Programme.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.2425
|
131.371
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
e)
|
Date
of the transaction
|
2017-10-12
|
f)
|
Place
of the transaction
|
n/a
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: October
16, 2017
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Sep 2024 to Oct 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2023 to Oct 2024